Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

JPM dispatches: Nvidia, Recursion, Dexcom and more

Jan 14, 2025 - statnews.com
The article discusses the ongoing efforts by U.S. health systems to eliminate clinical tools that use race to predict patient outcomes, as a federal deadline approaches for vetting these tools for discrimination. It highlights the broader challenge of addressing algorithms that incorporate race, sex, and other protected traits in patient care decisions. Additionally, the article covers Truveta's collaboration with Regeneron to integrate genomic data into its offerings, aiming to create a comprehensive dataset larger than existing projects like the UK Biobank. This initiative involves collecting exome sequences and linking them to de-identified medical records, backed by a $119 million investment.

The article also touches on various developments in health tech, including ResMed's strategy to leverage consumer tech for sleep apnea treatment, Nvidia's partnerships to enhance AI use in health and science, and Dexcom's focus on type 2 diabetes. It mentions Recursion Pharmaceuticals' progress in virtual cell modeling, Waystar's new AI tools for claims appeals, and significant fundraises by health AI companies. Additionally, Health Catalyst's acquisition of Upfront Healthcare Services and Teladoc Health's new CEO's priorities are noted. The article concludes with a list of related readings on topics such as Pfizer's CEO, hospital cybersecurity, and AI chatbots.

Key takeaways:

  • Hospitals in the U.S. are working to replace clinical tools that use race with race-free versions to avoid perpetuating inequitable care, with a federal deadline approaching in May.
  • Truveta, a health data company, is partnering with Regeneron to add genomic data to its offerings, aiming to create a project larger than the UK Biobank and NIH All of Us project.
  • Nvidia is forming partnerships with companies like IQVIA, Illumina, and Mayo Clinic to use AI and advanced computing in health and science, focusing on drug discovery and pathology model creation.
  • Dexcom is expanding its market for type 2 diabetes by pushing for coverage of its continuous glucose monitors and launching its CGM Stelo on Amazon.
View Full Article

Comments (0)

Be the first to comment!